Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Age-associated hydroxymethylation in human bone-marrow mesenchymal stem cells

  • Toraño, Estela G
  • Bayón, Gustavo F
  • del Real, Álvaro
  • Sierra, Marta I
  • García, María G
  • Carella, Antonella
  • Belmonte, Thalia
  • Urdinguio, Rocio G
  • Cubillo, Isabel
  • Garcia-Castro, Javier
  • Delgado-Calle, Jesús
  • Pérez-Campo, Flor M
  • Riancho, José A
  • Fraga, Mario F
  • Fernandez, Agustín F
BACKGROUND: Age-associated changes in genomic DNA methylation have been primarily attributed to 5-methylcytosine (5mC). However, the recent discovery of 5-hydroxymethylcytosine (5hmC) suggests that this epigenetic mark might also play a role in the process. METHODS: Here, we analyzed the genome-wide profile of 5hmc in mesenchymal stem cells (MSCs) obtained from bone-marrow donors, aged 2-89 years. RESULTS: We identified 10,685 frequently hydroxymethylated CpG sites in MSCs that were, as in other cell types, significantly associated with low density CpG regions, introns, the histone posttranslational modification H3k4me1 and enhancers. Study of the age-associated changes to 5hmC identified 785 hyper- and 846 hypo-hydroxymethylated CpG sites in the MSCs obtained from older individuals. CONCLUSIONS: DNA hyper-hydroxymethylation in the advanced-age group was associated with loss of 5mC, which suggests that, at specific CpG sites, this epigenetic modification might play a role in DNA methylation changes during lifetime. Since bone-marrow MSCs have many clinical applications, and the fact that the epigenomic alterations in this cell type associated with aging identified in this study could have associated functional effects, the age of donors should be taken into account in clinical settings.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression

  • Hindi, Nadia
  • Carrillo-García, Jaime
  • Blanco-Alcaina, Elena
  • Renshaw, Marta
  • Luna, Pablo
  • Durán, José
  • Jiménez, Natalia
  • Sancho, Pilar
  • Ramos, Rafael
  • Moura, David S.
  • Martín-Broto, Javier
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Rhabdomyosarcoma (RMS) in adults is a rare and aggressive disease, which lacks standard therapies for relapsed or advanced disease. This retrospective study aimed to describe the activity of BOMP-EPI (bleomycin, vincristine, methotrexate and cisplatin alternating with etoposide, cisplatin and ifosfamide), an alternative platinum-based regimen, in adult patients with relapsed/metastatic RMS. In the study, 10 patients with RMS with a median age at diagnosis of 20.8 years and a female/male distribution of 6/4 received a mean of 2.5 cycles of BOMP-EPI. The best RECIST response was a complete response in 1/10 (10%) patients, a partial response in 5/10 (50%), stable disease in 3/10 (30%) and progression in 1/10 (10%). With a median follow-up in the alive patients from the start of therapy of 30.5 months (15.7–258), all patients progressed with a median progression-free survival of 8.47 months (95% CI 8.1–8.8), and 7/10 patients died with a median overall survival of 24.7 months (95% CI 13.7–35.6). BOMP-EPI was an active chemotherapy regimen in adults with pediatric-type metastatic RMS, with outcomes in terms of survival that seem superior to what was expected for this poor-prognosis population. Low HMGB1 expression level was identified as a predictive factor of better response to this treatment., The authors thank the Instituto de Salud Carlos III (ISCIII)–Fondo Europeo de Desarrollo Regional (FEDER), project reference PI18/01728. The authors also thank the European Union’s Horizon 2020 research and innovation program, SELNET project No. 825806., This research was funded by IVAN PEREZ grant, GEIS number: GEISBECA2018. D.S.M. received a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

  • Codony-Servat, Jordi
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Asensio, Elena
  • Montironi, Carla|||0000-0002-1453-2193
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Marín Aguilera, Mercedes
  • Horndler, Carlos
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
  • Rubini, Michele
  • Jares, Pedro
  • Reig, Oscar|||0000-0003-1166-6943
  • Victoria, Iván
  • Gaba, Lydia
  • Martín-Richard, Marta|||0000-0003-4933-2463
  • Alonso Orduña, Vicente|||0000-0003-2280-1004
  • Escudero, Pilar
  • Fernández-Martos, Carlos
  • Feliu, Jaime|||0000-0003-4867-1420
  • Méndez, Jose Carlos
  • Méndez, Miguel
  • Gallego Plazas, Javier|||0000-0002-0584-1242
  • Salud, Antonieta
  • Rojo, Federico|||0000-0001-9989-0290
  • Castells, Antoni|||0000-0001-8431-2033
  • Prat, Aleix|||0000-0003-2377-540X
  • Rosell, Rafael|||0000-0003-0817-3400
  • García-Albéniz, Xabier
  • Camps Polo, Jordi|||0000-0003-2929-4228
  • Maurel, Joan|||0000-0002-9413-5592
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. We analysed time to progression, overall survival, and the mutational status of RAS, BRAF and nuclear p-IGF-1R expression by immunohistochemistry, in 470 metastatic CRC patients. The effect of IGF-1R activation and distribution was also assessed using cellular models of CRC and RNAi for functional validation. Nuclear IGF-1R increased in metastatic tumours compared to paired untreated primary tumours, and significantly correlated with poor overall survival in mCRC patients. In vitro, chemo-resistant cell lines presented significantly higher levels of IGF-1R expression within the nuclear compartment, and PIAS3, a protein implicated also in the sumoylation process of intranuclear proteins, contributed to IGF-1R nuclear sequestration, highlighting the essential role of PIAS3 in this process. Intriguingly, we observed that ganitumab, an IGF-1R blocking-antibody used in several clinical trials, and dasatinib, an SRC inhibitor, increased the nuclear localisation of IGF-1R. Our study demonstrates that IGF-1R nuclear location might lead to chemotherapy and targeted agent resistance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?

  • Rodríguez, Adela|||0000-0002-4899-6607
  • Esposito, Francis|||0000-0002-5028-9637
  • Oliveres, Helena|||0000-0003-1801-1181
  • Torres, Ferran|||0000-0002-7355-7913
The approval of a new drug for cancer treatment by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is based on positive, well-designed randomized phase III clinical trials (RCTs). However, not all of them are analyzed to support the recommendations. For this reason, there are different scales to quantify and evaluate the quality of RCTs and the magnitude of the clinical benefits of new drugs for treating solid tumors. In this review, we discuss the value of the progression-free survival (PFS) as an endpoint in RCTs and the concordance between it and the overall survival (OS) as a measure of the quality of clinical trial designs. We summarize and analyze the different scales to evaluate the clinical benefits of new drugs such as the The American Society of Clinical Oncology value framework (ASCO-VF-NHB16) and European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and the concordance between them, focusing on metastatic colorectal cancer (mCRC). We propose several definitions that would help to evaluate the quality of RCT, the magnitude of clinical benefit and the appropriate approval of new drugs in oncology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A novel nfix-stat6 gene fusion in solitary fibrous tumor, A case report

  • Moura, David S.
  • Díaz-Martín, Juan|||0000-0002-3985-6434
  • Bagué Rosell, Sílvia|||0000-0001-9980-7231
  • Orellana Fernández, Ruth|||0000-0003-1260-7064
  • Sebio, Ana|||0000-0003-3333-2370
  • Mondaza Hernandez, Jose Lucinio|||0000-0002-5642-3796
  • Salguero-Aranda, Carmen
  • Rojo, Federico|||0000-0001-9989-0290
  • Hindi, Nadia|||0000-0002-5864-762X
  • Fletcher, Christopher D.M.
  • Martín Broto, Javier|||0000-0001-7350-6916
Solitary fibrous tumor is a rare subtype of soft-tissue sarcoma with a wide spectrum of histopathological features and clinical behaviors, ranging from mildly to highly aggressive tumors. The defining genetic driver alteration is the gene fusion NAB2-STAT6, resulting from a paracentric inversion within chromosome 12q, and involving several different exons in each gene. STAT6 (sig-nal transducer and activator of transcription 6) nuclear immunostaining and/or the identification of NAB2-STAT6 gene fusion is required for the diagnostic confirmation of solitary fibrous tumor. In the present study, a new gene fusion consisting of Nuclear Factor I X (NFIX), mapping to 19p13.2 and STAT6, mapping to 12q13.3 was identified by targeted RNA-Seq in a 74-year-old female patient diagnosed with a deep-seated solitary fibrous tumor in the pelvis. Histopathologically, the neo-plasm did not display nuclear pleomorphism or tumor necrosis and had a low proliferative index. A total of 378 unique reads spanning the NFIXexon8-STAT6exon2 breakpoint with 55 different start sites were detected in the bioinformatic analysis, which represented 59.5% of the reads intersecting the genomic location on either side of the breakpoint. Targeted RNA-Seq results were validated by RT-PCR/ Sanger sequencing. The identification of a new gene fusion partner for STAT6 in solitary fibrous tumor opens intriguing new hypotheses to refine the role of STAT6 in the sarcomatogenesis of this entity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab, the BEYOND study (GEMCAD 17-01)

  • Aparicio Urtasun, Jorge
  • Virgili Manrique, Anna Cristina|||0000-0001-9733-6034
  • Capdevila Castillón, Jaume|||0000-0003-0718-8619
  • Muñoz Boza, F.
  • Galván, Patricia
  • Richart, P.
  • Oliveres, H.
  • Paez, David|||0000-0002-5596-6588
  • Hernando Cubero, Jorge
  • Serrano, S.
  • Vera, Ruth|||0000-0003-1524-3147
  • Hernandez-Yagüe, X.
  • Gallego, R.Á.
  • Riesco-Martinez, M.C.
  • García de Albeniz, X.
  • Maurel, Joan|||0000-0002-9413-5592
Purpose: Panitumumab plus FOLFOX (P-FOLFOX) is standard first-line treatment for RAS wild-type (WT) metastatic colorectal cancer. The value of panitumumab rechallenge is currently unknown. We assessed addition of panitumumab to FOLFIRI (P-FOLFIRI) beyond progression to P-FOLFOX in patients with no RAS mutations in liquid biopsy (LB). Methods: In this randomized phase II trial, patients were assigned (3:2 ratio) to second-line P-FOLFIRI (arm A) or FOLFIRI alone (arm B). LB for circulating tumor DNA analysis was collected at study entry and at disease progression. Primary endpoint was 6-month progression-free survival. Two-stage Simon design required 85 patients to be included (EudraCT 2017-004519-38). Results: Between February 2019 and November 2020, 49 patients were screened (16 RAS mutations in LB detected) and 31 included (18 assigned to arm A and 13 to arm B). The study was prematurely closed due to inadequate recruitment. Serious adverse events were more frequent in arm A (44% vs. 23%). Overall response rate was 33% (arm A) vs. 7.7% (arm B). Six-month progression-free survival rate was 66.7% (arm A) and 38.5% (arm B). Median progression-free survival was 11.0 months (arm A) and 4.0 months (arm B) (hazard ratio, 0.58). At disease progression, RAS or BRAF mutations in LB were found in 4/11 patients (36%) in arm A and 2/10 (20%) in arm B. Conclusions: The BEYOND study suggests a meaningful benefit of P-FOLFIRI beyond progression to P-FOLFOX in metastatic colorectal cancer patients with WT RAS status selected by LB. This strategy deserves further investigation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients, GEMCAD 1602 study

  • Español-Rego, Marta|||0000-0001-5497-2276
  • Fernández-Martos, Carlos
  • Elez, Elena|||0000-0002-4653-6324
  • Foguet, Carles
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Rodríguez, Nuria
  • Ruiz-casado, Ana
  • Pineda, Estela|||0000-0003-2128-747X
  • Cid, Joan|||0000-0001-5445-4508
  • Cabezón, Raquel
  • Oliveres, Helena|||0000-0003-1801-1181
  • Lozano, Miquel|||0000-0003-2593-833X
  • Ginés, Angels
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Ayuso Colella, Juan Ramón|||0000-0002-5306-6850
  • Pagés, Mario
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Torres, Ferran|||0000-0002-7355-7913
  • Thomson, Timothy
  • Cascante, Marta
  • Benítez Ribas, Daniel|||0000-0002-2346-5324
  • Torres, Ferran|||0000-0002-7355-7913
Immune check-point blockade (ICB) has shown clinical benefit in mismatch repair-deficient/microsatellite instability high metastatic colorectal cancer (mCRC) but not in mismatch repair-proficient/microsatellite stable patients. Cancer vaccines with autologous dendritic cells (ADC) could be a complementary therapeutic approach to ICB as this combination has the potential to achieve synergistic effects. This was a Phase I/II multicentric study with translational sub-studies, to evaluate the safety, pharmacodynamics and anti-tumor effects of Avelumab plus ADC vaccine in heavily pre-treated MSS mCRC patients. Primary objective was to determine the maximum tolerated dose and the efficacy of the combination. The primary end-point was 40% progression-free survival at 6 months with a 2 Simon Stage. A total of 28 patients were screened and 19 pts were included. Combined therapy was safe and well tolerated. An interim analysis (Simon design first-stage) recommended early termination because only 2/19 (11%) patients were disease free at 6 months. Median PFS was 3.1 months [2.1-5.3 months] and overall survival was 12.2 months [3.2-23.2 months]. Stimulation of immune system was observed in vitro but not clinically. The evaluation of basal RNA-seq noted significant changes between pre and post-therapy liver biopsies related to lipid metabolism and transport, inflammation and oxidative stress pathways. The combination of Avelumab plus ADC vaccine is safe and well tolerated but exhibited modest clinical activity. Our study describes, for the first-time, a de novo post-therapy metabolic rewiring, that could represent novel immunotherapy-induced tumor vulnerabilities. The online version contains supplementary material available at 10.1007/s00262-022-03283-5.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib

  • Hidalgo-Ríos, Samuel
  • Carrillo García, Jaime|||0000-0002-2861-3015
  • Moura, David S.
  • Stacchiotti, Silvia|||0000-0002-1742-8666
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Redondo Sánchez, Andrés|||0000-0002-7257-5642
  • Italiano, Antoine|||0000-0002-8540-5351
  • Gutiérrez, Antonio|||0000-0001-9062-077X
  • Grignani, Giovanni|||0000-0001-5515-569X
  • Hindi, Nadia|||0000-0002-5864-762X
  • López Guerrero, José Antonio|||0000-0002-7369-8388
  • Garcia del Muro, Xavier|||0000-0001-5571-2847
  • Martínez Trufero, Javier|||0000-0002-0997-2573
  • Palmerini, Emanuela|||0000-0003-3406-6705
  • Sebio, Ana|||0000-0003-3333-2370
  • Bernabeu, Daniel|||0000-0003-0828-9104
  • Le Cesne, Axel
  • Casali, Paolo Giovanni|||0000-0003-4056-8023
  • Blay, Jean-Yves|||0000-0001-7190-120X
  • Cruz-Jurado, Josefina|||0000-0001-6398-1641
  • Martín Broto, Javier|||0000-0001-7350-6916
Pazopanib was assessed prospectively in the GEIS-32 phase II study (NCT02066285) on advanced solitary fibrous tumour (SFT), resulting in a longer progression-free survival (PFS) and overall survival (OS) compared with historical controls treated with chemotherapy. A retrospective analysis of peripheral inflammatory indexes in patients enrolled into GEIS-32 was performed to evaluate their prognostic and predictive value. Patients received pazopanib 800 mg/day as the first antiangiogenic line. The impacts of baseline neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and red cell distribution width (RDW) on PFS, OS, and Choi response were evaluated by univariate and multivariate analysis. Metastasis-free interval (MFI), mitotic count, and ECOG were also included as potential prognostic factors. Sixty-seven SFT patients, enrolled in this study, showed a median age of 63 years and a female/male distribution of 57/43. The median follow-up from treatment initiation was 16.8 months. High baseline NLR, PLR, and standardised RDW were significantly associated with worse PFS and OS. NLR, RDW, MFI, and mitotic count were independent variables for PFS, while RDW and ECOG were independent for OS. Further, NLR and mitotic count were independent factors for Choi response. High baseline NLR and RDW values were independent prognostic biomarkers for worse outcome in advanced SFT patients treated with pazopanib.